Andre Paixao, MD
Cardiovascular Disease · Little Rock, ARNPI 1801051909
Payments from drug & device makers
Across 526 payments — averaging $333.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$88K
- Johnson & Johnson$60K
- Janssen Research & Development, LLC$20K
- Boston Scientific$2K
- Medtronic$2K
- Amgen$961
- plus $3K from 23 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2K
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$58,13580%
- Travel & lodging$3,3595%
- Food & beverage$10,80215%
- Education$50%
- Other$2820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 132 | $87,938 |
| Johnson & Johnson | 89 | $60,353 |
| Janssen Research & Development, LLC | 13 | $19,950 |
| Boston Scientific | 24 | $1,629 |
| Medtronic(2 entities) | 18 | $1,585 |
| Amgen | 62 | $961 |
| Novartis | 65 | $801 |
| Pfizer | 60 | $755 |
| E.r. Squibb & Sons, L.L.C. | 16 | $288 |
| Edwards Lifesciences | 3 | $276 |
| Merck | 7 | $174 |
| Penumbra, Inc. | 1 | $137 |
| Avinger Inc. | 1 | $121 |
| Amarin Pharma, Inc. | 6 | $117 |
| AstraZeneca | 7 | $92 |
| Alnylam Pharmaceuticals Inc. | 3 | $81 |
| Novo Nordisk | 3 | $48 |
| Opsens Inc. | 1 | $48 |
| Biosense Webster, Inc. | 1 | $35 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Inari Medical, Inc. | 1 | $28 |
| Siemens Medical Solutions USA, Inc. | 1 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
| W. L. Gore & Associates, Inc. | 1 | $17 |
| Surmodics, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Cardiovascular Systems Inc. | 2 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$59,270
- COREVALVE EVOLUT R$956
- AMPLATZER AMULET$892
- Watchman$831
- MitraClip$681
- PORTICO$282
- Portico Transcatheter Aortic Heart Valve$160
- CoreValve Evolut$152
- Xience Sierra Coronary Stent System$149
- Benchmark$137
- Farapulse$125
- MitraClip System$124
- Mitra Clip system$122
- PANTHERIS$121
- Edwards SAPIEN 3 Transcatheter Heart Valve$109
How this compares
$175,598 in reported general payments places this provider in the 90th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 845 | $700,870 |
| VyndamaxTafamidis | 28 | $619,545 |
| EntrestoSacubitril/Valsartan | 548 | $441,332 |
| XareltoRivaroxaban | 435 | $359,769 |
| Repatha SureclickEvolocumab | 134 | $101,596 |
| FarxigaDapagliflozin Propanediol | 135 | $97,546 |
| BrilintaTicagrelor | 52 | $31,276 |
| Praluent PenAlirocumab | 38 | $27,607 |
| Rosuvastatin Calcium | 1,854 | $17,636 |
| VascepaIcosapent Ethyl | 28 | $15,152 |
| Atorvastatin Calcium | 1,283 | $10,493 |
| Prasugrel Hcl | 102 | $8,036 |
| ClopidogrelClopidogrel Bisulfate | 867 | $7,165 |
| Metoprolol Succinate | 530 | $5,132 |
| Ezetimibe | 316 | $4,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $755 | $1,320,415873 claims |
| NovartisEntresto | $801 | $441,332548 claims |
| Johnson & JohnsonXarelto | $60,353 | $359,769435 claims |
| AstraZenecaFarxiga, Brilinta | $92 | $128,821187 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Little Rock
- Ian CawichLittle Rock$1.1M
- Christian Assad KottnerLittle Rock$670K
- Barry UretskyLittle Rock$609K
- William RollefsonLittle Rock$512K
- David JonesLittle Rock$473K
- Joe HargroveLittle Rock$464K
- Freddy ChrismanLittle Rock$283K
- David MegoLittle Rock$123K
- Daniel SherbetLittle Rock$90K
- Michael HuberLittle Rock$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.